
Extension of special sick pay scheme grants 'temporary relief' to nurses with long covid
The Labour Court has recommended a final extension to December. It had been controversially due to expire this week.
Fiona Walsh, a nurse living in Donnybrook, Cork, has been ill with long covid since January 2021.
She has seen little change with time, saying: 'it's been very disheartening'.
'We are very grateful for the six month extension. It's a welcome relief,' she said.
She and 158 other eligible staff had 'a very stressful day' on Thursday, waiting for the decision, she added.
'It's a temporary relief though, to be honest, as we all remain too unwell to return to work,' she said.
She supports a call from health unions for covid and long covid to be recognised as an occupational illness. This could lead to better supports.
Ms Walsh was one of a group of staff who met Taoiseach Micheál Martin on Friday.
'We presented to him the reality of living with long covid which we contracted while working on the frontline,' she said.
'He listened to what we presented him. He appreciates the work we did and is fully aware of the implications of long covid. He was very understanding and emphatic. We are so thankful he gave us his time.'
The Labour Court decision means after December 31 eligible staff can only transfer to the Public Service Sick Leave Scheme.
The Department of Health said Minister Jennifer Carroll MacNeill supports the decision, and will ensure the extension happens.
The ICTU Group of Healthcare Unions welcomed the decision and repeated its desire to see covid-19 and long covid recognized as occupational illness.
ICTU chairman Albert Murphy said this would place Ireland in line with other EU countries.
'Healthcare workers with long covid went to work when everyone else was told to stay at home during covid and are still suffering the consequences that come with a huge physical and mental cost,' he said.
Mr Murphy, also Irish Nurses and Midwives Director of Industrial Relations, called on the Government to take action.
Other unions in ICTU who support the move are Siptu, Forsa and the Medical Laboratory Scientists Association.
Labour health spokeswoman Marie Sherlock said Ireland is one of only two EU countries which does not recognise covid in this way.
'I have had many health workers express to me their enormous stress and anxiety about how they will pay their bills, mortgages, and look after their families,' she said.
She added: 'It is appalling that high court costs are wracked up by a case that workers felt they needed to take and that time was spent by department officials fighting trade unions at the Labour court.'
Read More
Online hospital dashboard lets public view a wealth of current Irish health data

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

The Journal
7 hours ago
- The Journal
The millionaire millennial seeking the presidency: How did Gareth Sheridan get so rich?
BUSINESSMAN GARETH SHERIDAN is seeking to become the youngest-ever Irish presidential candidate during this year's election, and claims to have secured support to make that possible. Much of the Irish public were introduced to 35-year-old Sheridan for the first time this week as a millionaire, pharmaceutical tycoon who recently returned to Ireland having spent the last seven years building up his company in the US. But how, exactly, did he earn his millions? And what does his company do? Acquisitions and mergers Nurtiband, a US-based healthcare-led company valued at approximately $80m, was started by Sheridan in 2012, during his final year at DIT in Dublin, where he was studying businesses and management. Taking inspiration from a transdermal patch his father had for a heart condition, Sheridan wrote his undergraduate thesis on providing properly-dosed medicine to patients through more accessible means, like patches, which are less likely to abuse. Early social media posts from Sheridan show that the company began by selling supplements, such as energy and metabolism-boosting patches, but the Dubliner wanted to branch out into the opioid market. Former Áras contender Seán Gallagher was later enlisted as the company's President (he has since left and has no current relationship with Sheridan) as the CEO worked towards getting the company listed on the Nasdaq stock exchange. Nutriband's strategy focused on carrying out a number of mergers and acquisitions, purchasing companies through its own stock options as a private company, over the last ten years, Sheridan explained on The Entrepreneur Experiment podcast in April. Sheridan focused on merging with firms with existing specialities in pharmaceuticals and biotechnology. It listed on the New York-based stock exchanged in October 2023, generating over $6m on its first day. Nutriband has now focused wholly on opioids through transdermal patches – similar to products used for nicotine-replacement therapy. Opioids, a type of pain-relief medication, have proven to be addictive among some patients. While they are an effective method to treat chronic pain, doctors – particularly in the US – have been reluctant to prescribe the medicines. Image posted by Sheridan in 2023 after his company was listed on the Nasdaq stock exchange in New York. Gareth Sheridan Gareth Sheridan As a result, more people have sought to purchase opioids illegally, and the black market drugs trade responded by introducing potent or synthetic alternatives over the last decade. The most-famous of these in the US is fentanyl, currently. Sheridan said that the most-important of Nutriband's acquisitions was the purchase of 4P Therapeutics in 2018, a company from two pharma veterans who created AVERSA technology , which prevents the misuse of opioids. It is today his lead product. During one acquisition, Nutriband pulled out of purchasing the manufacturer of transdermal patches . It was subsequently reported that a lawyer representing the firm did not disclose their ownership position in both companies. Asked about this on RTÉ Radio One yesterday, Sheridan explained that it was the only time that his firm had faced any trouble with US authorities and that, for Nutriband, it was seen as a minor issue and required the firm to correct submitted paperwork. Advertisement Unique selling point Sheridan has said he wants Nutriband to benefit those who are ill, developing patches that provide patients with a safe dose of medicines that are commonly abused – primarily opioids – targeting those who are in need of the controversial medicines. If abused, the drugs can cause long-term health complications, impact organ health and – in the case of synthetic and potent alternatives especially – minor doses can result in death. We're up and running! Excited to have announced my intention to seek a nomination for the upcoming Presidential election. I look forward to setting out my values and vision for the Presidency over the coming days and continuing to engage with Councillors across the country. — Gareth Sheridan (@GPSheridan1) August 11, 2025 Sheridan's business case is that there are still many people, in the US particularly, who need these pain medicines for proper health-related reasons. He believes the managed doses from his firm's patches is a unique selling point and a prevention of abuse and addiction. He said that there's been an increase of American patients being told to use over-the-counter pain medication for illnesses, and claims his patches could be a safer and more appropriate option. Pharmaceutical patches Sheridan in April said acquisitions and mergers were 'the strategy' for the company. Some of the previous owners from the purchased companies went on to join Sheridan and held positions at Nutriband for a short time. He explained, due to his own lack of expertise in pharmacology, he needed those who could help actually develop his ideas. He added: 'It also kept us away from expensive money. I am able to retain today a good proportion of the company because we didn't do angel [investor] rounds, seed rounds. We didn't do the traditional route.' News reports of the company's activities recently have focused on its newest patch, which would deliver a proper prescribed dose of fentanyl . The firm is still in ongoing discussions with the US's drugs regulator, the Food and Drug Administration. In preparation for its approval, it has offered shareholders particular stock options to raise funds. Success? Nutriband is yet to generate any revenue. In its most-recent public quarterly report, at the end of October last year, it recorded a net-loss of $1.3m. Speaking to The Entrepreneur Experiment in April, Sheridan said: 'In most public companies it's either one person makes a million dollars or, years later, dozens of people make multiple millions of dollars. So there's patience and trust involved.' The Áras hopeful, who has stepped back as CEO from Nutriband to pursuit the election later this year, said he is certain the company will be worth a billion dollars in the future. Sheridan said the firm has been careful not to waste any funding too: 'We've been very careful not to raise money that we don't need – money that is sitting in a bank account at the expense of shareholders [...] It's just little things like that.' He told RTÉ Radio One yesterday that he believes Nutriband will still achieve that goal, with or without him. He said that he intends to have a stake in the firm, should he be placed on the ballot and elected President. Sheridan said he is seeking to be nominated as a candidate to represent the interests of young people who feel that they must emigrate for work and other opportunities due to the housing situation here. He is due to announced his platform's values later this week. Readers like you are keeping these stories free for everyone... A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation. Learn More Support The Journal


Irish Independent
10 hours ago
- Irish Independent
State ‘completely failed' boy who died after waiting for scoliosis surgery
'What we went through was horrific' – families angry after Swiss clinic helped Irish woman to die in secret despite its promises


Sunday World
15 hours ago
- Sunday World
Mum makes desperate plea to aid young son's battle with rare muscle-wasting disease
'I hope that this €38k-a-month medicine – if we can get it – will give Archie hope' But determined Una Ennis is vowing to continue fighting to raise more money until she reaches the target of €3.2m, which would would allow her son Archie (8) get on to a ground-breaking gene therapy programme. Una also today pleads with the government to allow the rollout of a special medicine called Givinostat, which would help Archie and around 110 other boys in Ireland with Duchenne Muscular Dystrophy slow down the worsening of the disease. Brave Archie and his mum She confirms the cost of the drug is horrendously expensive, at €38,000 a bottle per month, but stressed every child's life is priceless. The healthcare worker from Jobstown in Tallaght, Dublin, along with other parents of Duchenne boys recently protested outside the Dáil about their plight, and met with health minister Jennifer Carroll MacNeill. 'It's absolutely devastating to have this diagnosis for your child and not having access to medicine to treat it. All we want to do is save our little boy,' Una (32) tells the Sunday World . 'If a child in Ireland has cancer, they are given chemo. If a child in Ireland has Duchenne, they're given a wheelchair and a steroid — and it's just not acceptable. How do I explain this to my little boy? Read more 'I hope this medication, if we get it, can give him some hope. 'Givinostat will slow down the progression of the disease. It will keep the boys on their feet for longer. It will give them a longer life expectancy and slow everything down.' Una and her husband Kenneth (33), who is a sergeant in the army, were given the devastating news about their son's diagnosis late last year. 'For years we thought 'what's going on?' and thought he was just being a little boy and taking his time. 'But when he was struggling to get up the stairs and things started to regress we thought 'something's really wrong here'. Then we got the test results, it was just a nightmare,' she recalls. Eight-year-old Archie Ennis The couple, who also have a four-year-old girl, Maisie, were told the devastating effects of the disease, which affects one in 5,000 boys. One in five million girls get the disease, but the symptoms are different and there are no documented Irish sufferers. 'This is a rare genetic condition that will weaken Archie's muscles,' she explains. 'It will start to weaken Archie's muscles in his hips and then in his shoulders. The doctor said that it will progress over time to weaken his heart and his lungs. 'She also told us most boys with this condition will end up in a wheelchair at the age of 10.' Life expectancy is generally in the early 30s. 'Archie is currently struggling with his splints that he wears at night time. There is a place in America I'd like to bring him, to see if we can get something to suit him,' she notes. Since news broke of the family's turmoil there has been huge fundraising activities, especially in the Tallaght area and with Alan's army colleagues. Eight-year-old Archie Ennis is fighting Duchenne Muscular Dystrophy News in 90 Seconds - August 12th 'The GoFundMe people would donate online but a lot of people have been giving cash, a lot of people have been giving through Revolut, so whenever they give me that money I put into the Archie trust, which will be fully completed next week,' she explains. 'As of now the gene therapy that we originally wanted to go for [in America], there's a lot of symptoms with it, and three little boys have passed away from receiving this gene therapy, which I am obviously very nervous [about] and don't want to give him that one. 'But as time has been going on there's been another gene therapy that's been rolled out and the data on that is meant to be amazing. 'When that is passed, can you imagine the price of that one which is meant to be better than the original one? It's not ready yet but we're going to keep continuing to fundraise until it's out, and then we will be able to get that gene therapy for Archie. 'But I've only got two years because as Archie gets older, he's more prone to an infection that's actually in the gene therapy. If I don't get it within two years then Archie won't be eligible to receive the medicine.' That is why they want Givinostat in the meantime, to slow down the progression of the disease. 'If the government help us and give us this drug, the boys would stay on their feet a lot longer and live a lot longer,' she stresses. Una has had to reduced her work hours to keep up Archie's medical appointments. 'If we got €3.2 million we would be one step ahead. We would be ready and waiting for that drug to be passed and we'd be there to get the first dose.' Donations can be made on the GoFundMe page at or by Revolut @unacl6jg